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Background
In this randomized clinical trial, we aimed to determine whether increasing the 
frequency of in-center hemodialysis would result in beneficial changes in left ven-
tricular mass, self-reported physical health, and other intermediate outcomes among 
patients undergoing maintenance hemodialysis.
Methods
Patients were randomly assigned to undergo hemodialysis six times per week (frequent 
hemodialysis, 125 patients) or three times per week (conventional hemodialysis, 120 
patients) for 12 months. The two coprimary composite outcomes were death or 
change (from baseline to 12 months) in left ventricular mass, as assessed by cardiac 
magnetic resonance imaging, and death or change in the physical-health composite 
score of the RAND 36-item health survey. Secondary outcomes included cognitive 
performance; self-reported depression; laboratory markers of nutrition, mineral me-
tabolism, and anemia; blood pressure; and rates of hospitalization and of interven-
tions related to vascular access.
Results
Patients in the frequent-hemodialysis group averaged 5.2 sessions per week; the week-
ly standard Kt/Vurea (the product of the urea clearance and the duration of the dialysis 
session normalized to the volume of distribution of urea) was significantly higher in the 
frequent-hemodialysis group than in the conventional-hemodialysis group (3.54±0.56 
vs. 2.49±0.27). Frequent hemodialysis was associated with significant benefits with 
respect to both coprimary composite outcomes (hazard ratio for death or increase in 
left ventricular mass, 0.61; 95% confidence interval [CI], 0.46 to 0.82; hazard ratio for 
death or a decrease in the physical-health composite score, 0.70; 95% CI, 0.53 to 0.92). 
Patients randomly assigned to frequent hemodialysis were more likely to undergo 
interventions related to vascular access than were patients assigned to conventional 
hemodialysis (hazard ratio, 1.71; 95% CI, 1.08 to 2.73). Frequent hemodialysis was 
associated with improved control of hypertension and hyperphosphatemia. There were 
no significant effects of frequent hemodialysis on cognitive performance, self-reported 
depression, serum albumin concentration, or use of erythropoiesis-stimulating agents.
Conclusions
Frequent hemodialysis, as compared with conventional hemodialysis, was associ-
ated with favorable results with respect to the composite outcomes of death or 
change in left ventricular mass and death or change in a physical-health composite 
score but prompted more frequent interventions related to vascular access. (Funded 
by the National Institute of Diabetes and Digestive and Kidney Diseases and others; 
ClinicalTrials.gov number, NCT00264758.)
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When 90% or more of usual kidney function is lost, either kidney transplan-tation or dialysis is required to sustain 
life. Nearly 400,000 persons in the United States 
and 2 million worldwide are dependent on dialy-
sis; of these, approximately 90% in the United 
States and 70% in Canada undergo hemodialysis, 
which is typically delivered three times a week.1 
The rationale for thrice-weekly hemodialysis was 
derived from a combination of physiological ex-
periments, assessments of patient acceptance, 
feasibility, logistics, and costs.2-4 Mortality re-
mains high (approximately 18 to 20% per year) 
despite improvements in the technology for dialy-
sis, the development of new pharmaceutical 
agents, and experience over the course of more 
than 40 years since maintenance dialysis became 
available. Moreover, although dialysis can sustain 
life, it rarely restores health; patients undergoing 
dialysis have considerable complications (includ-
ing frequent and extended hospitalizations)1 and 
relatively poor functional status and health-related 
quality of life.5-7
The optimal “dose” of hemodialysis remains 
uncertain. Anchored to a thrice-weekly regimen 
and typically expressed as a metric of small-
solute (urea) clearance, dialysis dosing has been 
informed by numerous observational studies8-10 
and a few carefully conducted, randomized clini-
cal trials.11,12 Despite ample observational data 
suggesting that the dose of hemodialysis (ex-
pressed as the per-session Kt/Vurea, which is the 
product of the urea clearance and the duration of 
the dialysis session normalized to the volume 
of distribution of urea) correlates directly with 
survival, the Hemodialysis (HEMO) Study showed 
that there was no benefit from more intensive 
hemodialysis (higher per-session Kt/Vurea) when 
patients underwent hemodialysis three times a 
week.12 However, solute removal can be dramati-
cally augmented by increasing the frequency of 
hemodialysis sessions.13 Several uncontrolled 
studies showed that there were significant im-
provements in patient-reported outcomes and re-
sults of laboratory tests when patients were treated 
with more frequent in-center or at-home hemo-
dialysis.14,15 Because of ongoing uncertainty re-
garding the optimal dose of hemodialysis, we 
tested the hypothesis that frequent (six times per 
week) in-center hemodialysis, as compared with 
conventional thrice-weekly hemodialysis, would 
improve an array of objective and patient-reported 
outcomes.
Me thods
Study Protocol
The Frequent Hemodialysis Network (FHN) Daily 
Trial was a multicenter, prospective, randomized, 
parallel-group trial of frequent (six times per 
week), as compared with conventional (three times 
per week) in-center hemodialysis. The study was 
conducted between January 2006 and March 
2010 at 11 university-based and 54 community-
based hemodialysis facilities in North America 
(for a list of participating sites, see the Supple-
mentary Appendix, available with the full text of 
this article at NEJM.org). The design of the FHN 
Daily Trial has been described previously.16
The FHN Daily Trial and a companion Noctur-
nal Trial (ClinicalTrials.gov number, NCT00271999) 
were sponsored by the National Institute of Dia-
betes and Digestive and Kidney Diseases and the 
Centers for Medicare and Medicaid Services, with 
additional support from DaVita, Dialysis Clinics, 
Fresenius Medical Care, Renal Advantage, Renal 
Research Institute, and Satellite Healthcare. The 
dialysis companies donated several weekly dialy-
sis sessions; they had no role in the design of the 
study or in the analysis of the data. Recruitment 
and data collection were performed by site inves-
tigators and study coordinators. An independent 
data and safety monitoring board reviewed the 
safety data and interim results. The study was 
approved by the institutional review board at each 
participating study site. The protocol for the study, 
including the statistical analysis plan, is available 
at NEJM.org. The authors attest to the fidelity of 
this report to the trial protocol.
Study Population
Specific inclusion and exclusion criteria are listed 
in Table 1 in the Supplementary Appendix. Written 
informed consent was obtained from all patients 
18 years of age or older; patient assent and writ-
ten parental consent were obtained from partici-
pants younger than 18 years of age.
Study Design
Randomization
Randomization was stratified according to clini-
cal center and diabetes status, with the use of 
randomly permuted blocks. Although treatment 
assignments could not be concealed, between-
group comparisons of the outcomes were con-
cealed from the investigators throughout the 
course of the trial.
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Intervention
After randomization, prescriptions for dialysis 
were determined centrally and were transmitted 
to each clinical center. Patients who were assigned 
to thrice-weekly hemodialysis (120 patients) con-
tinued their usual dialysis prescriptions, which in-
cluded a minimum target equilibrated Kt/Vurea of 
1.1 and a session length of 2.5 to 4.0 hours. The 
equilibrated Kt/Vurea is the ratio of the equilibrated 
urea clearance during each dialysis session (Kt) to 
the patient’s volume of urea distribution (V).17 The 
target equilibrated Kt/Vn, where Vn = 3.271 × V2/3, 
in the group that underwent hemodialysis six 
times per week (125 patients) was 0.9 provided 
that the length of the session was between 1.5 
and 2.75 hours. These prescriptions were factored 
by V2/3 rather than V (similar to scaling surface 
area from body mass) to reduce the dependence 
of dialysis prescriptions on body mass and to 
avoid unfeasibly long dialysis treatments for pa-
tients with large body mass. Simulation studies 
indicated that these interventions would provide 
substantial differences in targeted weekly stan-
dard Kt/Vurea between the treatment groups.
Other Measurements
We obtained data on demographic characteristics 
at baseline, with clinical data and laboratory-test 
results obtained at baseline and serially over the 
course of the study. We calculated adherence as 
the ratio of outpatient dialysis sessions attended 
to outpatient dialysis sessions prescribed, by 
month. We obtained standardized assessments 
of coexisting conditions with the use of a modi-
fied version of the Charlson Comorbidity Index18 
supplemented with additional items from the In-
dex of Coexistent Diseases.19 Questionnaires were 
administered by telephone in either English or 
Spanish through a centralized call center; per-
sonnel administering the questionnaire were un-
aware of the participants’ intervention assign-
ment. Cardiac magnetic resonance imaging (MRI) 
was performed with the use of a standardized 
protocol; images were analyzed in a blinded 
fashion at a central core laboratory. A committee 
overseeing standards of care periodically reviewed 
and reported to the clinical centers the results of 
prespecified measures (serum phosphate and bi-
carbonate and blood hemoglobin concentrations; 
normalized protein nitrogen appearance; and 
blood pressure relative to the achieved target 
weight after dialysis) that were outside the ranges 
recommended in published guidelines.
Outcomes
It was not feasible to recruit a sample large enough 
to provide adequate statistical power to assess 
individual end points of death, cause-specific 
death, hospitalization, or other events. Therefore, 
we selected two composite coprimary outcomes: 
death or 12-month change in left ventricular 
mass, as assessed by cardiac MRI, and death or 
12-month change in the physical-health compos-
ite score from the RAND 36-item health survey 
(RAND-36).20 We determined that favorable ef-
fects on both coprimary outcomes would be re-
quired to provide evidence of overall benefit. We 
selected nine domains for secondary analysis; 
within eight of those domains, we selected a main 
secondary outcome: for the domain of cardiovas-
cular structure and function, the outcome was 
left ventricular mass; for the domain of physical 
health, the outcome was the physical-health com-
posite score of the RAND-36; for the domain of 
mental health, the outcome was the score on the 
Beck Depression Inventory; for the domain of 
cognitive function, the outcome was the score 
on the Trail Making Test, Part B; for the domain 
of nutrition, the outcome was the serum albumin 
concentration before dialysis; for the domain of 
mineral metabolism, the outcome was the serum 
phosphorus concentration before dialysis; for the 
domain of anemia, the outcome was the dose of 
an erythropoiesis-stimulating agent; and for the 
domain of death and hospitalization, the outcome 
was the rate of the composite of death or the first 
hospitalization unrelated to vascular access. For 
the ninth domain, hypertension, we specified two 
main secondary outcomes: systolic blood pres-
sure before dialysis and the number of antihyper-
tensive agents the patient was taking. We focused 
on several potential risks, including the need for 
interventions related to vascular access. Deaths, 
hospitalizations, and complications related to vas-
cular access were adjudicated by an outcomes 
committee whose members were unaware of the 
patients’ intervention assignment. Complications 
related to vascular access were defined as access 
failure, infection requiring a procedure, thrombec-
tomy, angioplasty, and fibrin stripping of cathe-
ters or replacement of catheters.
Statistical Analysis
We used the Hochberg modification of the Bonfer-
roni procedure to provide a studywide two-sided 
significance level approximating 0.05 when con-
sidering the two coprimary composite outcomes.21 
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Assuming a 20% reduction in mortality with fre-
quent hemodialysis, we estimated that a sample 
size of 250 participants would give the study 90% 
power to detect clinically meaningful mean reduc-
tions in left ventricular mass of 12.1 to 13.3 g and 
increases in the physical-health composite score 
of the RAND-36 (in which scores range from 0 to 
100 and higher scores indicate better physical 
status) of 4.6 to 5.0 points, with the detectable 
effect on each coprimary outcome varying slight-
ly depending on the size of the treatment effect 
on the other coprimary end point.
Table 1. Baseline Characteristics of the Study Participants.*
Characteristic
Conventional  
Hemodialysis
(N = 120)
Frequent 
Hemodialysis
(N = 125) P Value
Age (yr) 52.0±14.1 48.9±13.6 0.07
Female sex (%) 39.2 37.6 0.80
Race or ethnic group (%)† 0.32
Black 44.2 39.2
White 38.3 34.4
Native American, Aboriginal Canadian, Alaskan Native, 
or First Nation
3.3 3.2
Asian 4.2 8.8
Native Hawaiian or other Pacific Islander 2.5 0.8
Other or mixed 7.5 13.6
Body-mass index‡ 27.5±7.1 27.3±6.5 0.82
Weight after dialysis (kg) 78.7±20.5 77.6±20.6 0.68
Anthropometric volume (liters)§ 39.5±8.3 39.3±8.1 0.90
Cause of end-stage renal disease (%) 0.89
Diabetic nephropathy 32.5 36.0
Glomerulonephritis 19.2 19.2
Hypertensive nephrosclerosis 20.0 21.6
Polycystic kidney disease 5.0 3.2
Other 23.3 20.0
Duration of end-stage renal disease (%) 0.38
<2 yr 16.7 16.0
2–5 yr 42.5 35.2
>5 yr 40.8 48.8
Coexisting medical conditions (%)
Hypertension 87.3 91.5 0.12
Myocardial infarction 13.3 8.8 0.26
Heart failure 20.0 20.0 1.00
Atrial fibrillation 7.5 4.0 0.24
Peripheral arterial disease 8.3 12.0 0.34
Abdominal aortic aneurysm repair or bypass grafting 1.7 2.4 0.68
Stroke 7.5 7.2 0.93
Dementia 0.8 0.0 0.31
Tumor without metastases 6.7 1.6 0.04
Diabetes and complications of diabetes 41.7 40.0 0.79
Hemiplegia 0.8 1.6 0.59
Chronic pulmonary disease 4.2 4.8 0.81
Moderate or severe liver disease 0.8 0.8 0.98
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The analysis of the coprimary composite out-
comes was performed with the use of a rank-
based procedure, as follows: patients who died 
before 12 months were ranked from lowest (in-
dicating the poorest outcome) to highest on the 
basis of survival time before death. Patients who 
survived 12 months were ranked on the basis of 
a favorable or unfavorable change in left ventricu-
lar mass (or physical-health composite score of 
the RAND-36) from baseline to 12 months. We 
right-censored (i.e., censoring when the event had 
not yet occurred at the time of measurement) 
patients at the time of transplantation or loss to 
follow-up, so that patients who survived but did 
not provide measurements of left ventricular mass 
(or physical-health composite score) were includ-
ed as 1-year survivors. We compared ranks be-
tween treatment groups with the use of the 
log-rank test and calculated hazard ratios and 
95% confidence intervals with the use of Cox 
proportional-hazards regression. We prespecified 
subgroup analyses according to sex, history or 
no history of heart disease, anthropometric vol-
ume (volume calculated with the use of the Wat-
son equation, <35 liters vs. ≥35 liters), duration 
of end-stage renal disease (<4 years vs. ≥4 years), 
and presence or absence of residual kidney func-
tion (defined as >100 ml of daily urine volume). 
We analyzed the time to death or first hospital-
ization unrelated to vascular access using Cox 
regression, and we used the Andersen–Gill meth-
od for the analysis of recurrent events. All analy-
ses were performed according to the intention-
to-treat principle. Analytic methods used for the 
quantitative secondary outcomes are described 
in the Supplementary Appendix. We performed 
analyses of the main secondary outcomes with-
out adjusting for multiple comparisons. Statisti-
cal analyses were performed with the use of SAS 
software, version 9.2 (SAS Institute).
R esult s
Study Population
Between January 1, 2006, and March 31, 2009, a 
total of 378 patients were enrolled, and 245 un-
derwent randomization (Fig. 1 in the Supplemen-
tary Appendix). As shown in Table 1, the base-
Table 1. (Continued.)
Characteristic
Conventional 
Hemodialysis
(N = 120)
Frequent 
Hemodialysis
(N = 125) P Value
Residual kidney function (%) 0.17
Anuria 60.0 72.0
>0 to 1 ml/min 15.8 14.4
>1 to 3 ml/min 24.2 13.6
Diastolic blood pressure before dialysis (mm Hg) 78.4±11.7 81.0±11.2 0.08
Serum creatinine (mg/dl)¶ 10.3±2.5 10.8±3.0 0.21
Kt/Vurea‖
Weekly standard 2.54±0.39 2.50±0.31 0.45
Equilibrated 1.43±0.28 1.43±0.25 0.94
Dialysis access (%)** 0.86
Fistula 62.5 65.6
Synthetic graft 18.3 16.0
Catheter 19.2 18.4
*  Plus–minus values are means ±SD.
†  Race or ethnic group was self-reported.
‡  The body-mass index is the weight in kilograms divided by the square of the height in meters.
§  Anthropometric volume was calculated with the use of the Watson equation.
¶  To convert the values for creatinine to micromoles per liter, multiply by 88.4.
‖  The weekly standard Kt/Vurea is defined as the ratio of the generation rate of urea to the average urea concentration be-
fore dialysis and is commonly used to compare small-molecule clearance among different methods and schedules of di-
alysis.22 The equilibrated Kt/V (the ratio of the equilibrated urea clearance during each dialysis session [Kt] to the pa-
tient’s urea distribution volume [V]) is computed with the use of a modified Tattersall correction to single-pool Kt/V.17
** The proportions of upper arm and forearm fistulas were 47% and 52%, respectively; the proportions of upper arm 
and forearm grafts were 62% and 29%, respectively.
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line characteristics of the participants in the two 
study groups were similar; the study population 
was diverse with respect to age, sex, race or eth-
nic group, the primary cause of kidney disease, 
coexisting conditions, income, and education; the 
median duration of end-stage renal disease was 
3.6 years (10th and 90th percentiles, 0.6 and 14.3).
Characteristics of the Study Intervention
Details of the characteristics of the intervention 
are provided in Table 2. A total of 78% of the 
patients who were assigned to undergo hemodi-
alysis six times per week attended at least 80% of 
the prescribed hemodialysis sessions. As expect-
ed, the per-session dialysis dose, ultrafiltration 
volume, and weight gain between dialysis ses-
sions were lower, and corresponding weekly val-
ues were higher, in the group that underwent 
hemodialysis six times per week than in the group 
that underwent the procedure three times per 
week. Figure 2 in the Supplementary Appendix 
shows the number of treatments per week, the 
Table 2. Features of Intervention.*
Variable
Conventional 
Hemodialysis
(N = 120)
Frequent 
Hemodialysis
(N = 125)
Ratio of Means 
(Frequent vs.  
Conventional) P Value
Hemodialysis treatments per week (no.) 2.88±0.39 5.17±1.11 1.80 <0.001
Expected treatments attended (% of patients)†
>80% 94.9 77.7 — <0.001
65–80% 3.4 8.0 —
<65% 1.7 14.4 —
Time per dialysis session (min) 213±28 154±25 0.72 <0.001
Total dialysis time per week (hr) 10.4±1.6 12.7±2.2 1.23 <0.001
Blood flow rate (ml/min) 402±41 396±42 0.99 0.26
Dialysate flow rate (ml/min) 710±106 747±68 1.05 0.001
Dialyzer urea clearance (ml/min) 269±22 271±21 1.01 0.47
Ultrafiltration
Per session (liters) 3.06±0.99 2.12±0.74 0.69 <0.001
Per session (% of weight after dialysis) 3.99±1.26 2.83±1.00 0.71 <0.001
Per week (liters) 8.99±3.03 10.58±3.83 1.18 <0.001
Kt/Vurea‡
Total weekly standard 2.57±0.26 3.60±0.57 1.40 <0.001
Dialysis weekly standard 2.49±0.27 3.54±0.56 1.42 <0.001
Equilibrated per session 1.41±0.21 1.06±0.21 0.75 <0.001
Blood urea nitrogen (mg/dl)§
Before dialysis 58.4±13.8 46.5±14.4 0.80 <0.001
After dialysis 15.9±4.9 16.5±5.6 1.04 0.38
* Plus–minus values are means ±SD. With the exception of number of treatments per week and treatments attended, all 
treatment features were first averaged over each patient’s first modeled dialyses (sessions in which solutes are mea-
sured before and after the session) over each month of follow-up. Treatment attendance was monitored for all sessions 
during the time that the patient remained under the care of investigators at the participating centers.
† Adherence rates of 65% and 80% represent an average of 1.95 and 2.40 treatments per week, respectively, in the con-
ventional-hemodialysis group and 3.9 and 4.8 treatments per week, respectively, in the frequent-hemodialysis group.
‡ The weekly standard Kt/Vurea is defined as the ratio of the generation rate of urea to the average urea concentration be-
fore dialysis and is commonly used to compare small-molecule clearance among different methods and schedules of 
dialysis.22 The dialysis weekly standard is the component of the total weekly standard Kt/Vurea that remains after correc-
tion for residual renal function.23 The equilibrated Kt/V (the ratio of the equilibrated urea clearance during each dialysis 
session [Kt] to the patient’s urea distribution volume [V]) is computed with the use of a modified Tattersall correction 
to single-pool Kt/V.17
§ To convert the values for blood urea nitrogen to millimoles per liter, multiply by 0.357.
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weekly treatment time, and the weekly standard23 
Kt/Vurea in both treatment groups.
Coprimary Outcomes
Five patients in the frequent-hemodialysis group 
died, as compared with 9 in the conventional-
hemodialysis group; 11 patients in the frequent-
hemodialysis group underwent transplantation, 
as compared with 13 in the conventional-hemo-
dialysis group. Of the 5 patients in the frequent-
hemodialysis group who died, 4 died suddenly, 
and the fifth died from hemorrhage (from the vas-
cular access). In the conventional-hemodialysis 
group, 3 patients died suddenly, and 1 each died 
from myocardial infarction, stroke, sepsis, lung 
cancer, hemorrhage (from the gastrointestinal 
tract), and enterocolitis. Data on left ventricular 
mass at 12 months were missing for 22 patients, 
and data on baseline or 12-month RAND-36 phys-
ical-health composite scores were missing for 12 
patients. Overall, the composite outcome of death 
or change in left ventricular mass was ascertained 
in 199 patients, and the composite outcome of 
death or change in the RAND-36 physical-health 
composite score was ascertained in 211.
Frequent hemodialysis was associated with fa-
vorable changes in both coprimary outcomes 
(hazard ratio for death or increase in left ventricu-
lar mass, 0.61; 95% confidence interval [CI], 0.46 
to 0.82; hazard ratio for death or a decrease in the 
RAND-36 physical-health composite score, 0.70; 
95% CI, 0.53 to 0.92) (Fig. 1A and 1B). The effects 
of frequent hemodialysis on the coprimary com-
posite outcomes were not appreciably different in 
subgroups according to sex, history or no history 
of heart disease, anthropometric volume, duration 
of end-stage renal disease, or presence or absence 
of residual kidney function (data not shown).
Secondary Outcomes
There was no significant effect of frequent hemo-
dialysis on the composite outcome of death or 
hospitalization unrelated to vascular access (haz-
ard ratio, 0.93; 95% CI, 0.62 to 1.39). The adjust-
ed mean (±SE) left ventricular mass decreased by 
16.4±2.9 g in patients in the frequent-hemodialy-
sis group, as compared with 2.6±3.2 g in patients 
in the conventional-hemodialysis group (P<0.001). 
Patients in the frequent-hemodialysis group had 
an increase in adjusted mean RAND-36 physical-
health composite score of 3.4±0.8; the corre-
sponding change in patients in the conventional-
hemodialysis group was 0.2±0.8 (P = 0.004) (Fig. 3 
in the Supplementary Appendix). Frequent hemo-
dialysis was associated with significantly improved 
control of hypertension and hyperphosphatemia. 
Table 3 shows the baseline and 12-month results 
for the main secondary outcomes; standardized 
changes in the secondary outcome domains are 
shown in Figure 1C.
Complications of Therapy
As compared with patients in the conventional-
hemodialysis group, patients undergoing frequent 
hemodialysis were more likely to undergo inter-
ventions related to vascular access, both in the 
analysis of the time to the first intervention (haz-
ard ratio, 1.71; 95% CI, 1.08 to 2.73) (Fig. 4 in the 
Supplementary Appendix) and in the analysis of 
multiple interventions (hazard ratio, 1.35; 95% CI, 
0.84 to 2.18). There were 95 interventions related 
to vascular access (19 interventions to correct ac-
cess failure and 76 other procedures) in the fre-
quent-hemodialysis group and 65 interventions 
(23 to correct access failure and 42 other proce-
dures) in the conventional-hemodialysis group; 
47% of the patients in the frequent-hemodialysis 
group underwent at least one procedure, as com-
pared with 29% in the conventional-hemodialy-
sis group. The percentages of events affecting 
fistulas, grafts, and catheters were 51%, 32%, 
and 17%, respectively, in the frequent-hemodialy-
sis group and 48%, 38%, and 14%, respectively, 
in the conventional-hemodialysis group.
The rates of adverse events are summarized 
in Table 4. Episodes of hypotension during di-
alysis in relation to the number of treatments 
were less common in the frequent-hemodialysis 
group than in the conventional-hemodialysis 
group (10.9% vs. 13.6% of monitored sessions 
with at least one recorded episode, P = 0.04).
Discussion
In this multicenter, randomized trial of frequent, 
as compared with conventional, in-center hemo-
dialysis, we observed statistically significant and 
clinically meaningful benefits with respect to 
both coprimary composite end points — death or 
12-month change in left ventricular mass and 
death or 12-month change in self-reported physi-
cal health.
Our results extend those that have been shown 
in several observational studies and clinical trials 
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comparing conventional and more frequent he-
modialysis. DePalma et al.25 reported the initial 
findings regarding an increased frequency of he-
modialysis more than 40 years ago; in 1988, 
Buoncristiani et al.26 found that control of hy-
pertension and multiple metabolic factors were 
improved when patients underwent hemodialysis 
five to six times per week. Ting et al.27 showed 
that among 42 patients who responded poorly to 
conventional hemodialysis, frequent in-center he-
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modialysis was associated with fewer days in the 
hospital, improved health-related quality of life, 
and improved control of hypertension and ane-
mia. Ayus et al.28 compared 23 patients under-
going frequent in-center hemodialysis with 51 
matched controls and found that patients un-
dergoing frequent hemodialysis had a reduction 
in left ventricular hypertrophy and lower concen-
trations of phosphate and C-reactive protein. Other 
studies have examined the effects of frequent 
home-based hemodialysis, often performed over-
night (so-called nocturnal hemodialysis).29,30
Although these studies were pioneering, they 
were limited by small sample sizes, inadequate or 
no controls, selection bias, dropout bias, and an 
emphasis on within-group, rather than between-
group, inference tests. We elected not to allow 
participants to perform frequent hemodialysis at 
home, so that the benefits and risks of home-
based therapies and the effects of session fre-
quency could be disentangled.
In the conventional-hemodialysis group, the 
prescribed dialysis dose was at or above the levels 
recommended in clinical practice guidelines. In 
both groups, other aspects of hemodialysis and 
related care were standardized and monitored. 
Given the excellent adherence to both treatment 
regimens, the difference between the groups with 
respect to solute clearance was maintained. The 
vast majority of participants in the frequent-
hemodialysis group completed at least five ses-
sions per week; participants in the conventional-
hemodialysis group rarely had extra hemodialysis 
sessions.
The trial met its prespecified criteria for show-
ing overall benefit. The results of the FHN Daily 
Trial can be compared with those of the HEMO 
Study,12 in which 1846 patients were randomly 
assigned to conventional or more intensive thrice-
weekly in-center hemodialysis. In the HEMO 
Study, there was no overall effect on mortality, 
the rate of hospitalization, or health-related qual-
ity of life among patients randomly assigned to 
a target per-session equilibrated Kt/Vurea of 1.45 
or 1.05, although subgroup analyses suggested a 
possible benefit among women and a trend to-
ward harm among men with the more intensive 
treatment.31 It is possible that the benefit we 
observed in the FHN trial among patients in the 
frequent-hemodialysis group was due to an even 
greater between-group difference with respect to 
urea clearance, a marker of low-molecular-weight 
solutes. Alternatively, the benefit of frequent 
hemodialysis may result from improved control 
of other metabolic by-products, such as phos-
phate or other retained uremic solutes, more 
physiologic removal of solutes (yielding lower 
Figure 1 (facing page). Coprimary Composite Outcomes 
and Main Secondary Outcomes.
Kaplan–Meier curves are shown for the composite out-
comes of death or change in left ventricular (LV) mass 
(Panel A) and death or change in the physical-health 
composite (PHC) score from the RAND 36-item health 
survey (Panel B). For each value for the coprimary com-
posite outcome on the horizontal axis, the Kaplan–
Meier curve indicates the proportion of patients in the 
respective treatment groups with an equal or more fa-
vorable outcome. The horizontal distance between the 
Kaplan–Meier curves at the 50% value on the vertical 
axes indicates the median composite outcome results. 
Median outcomes for the composite outcome of death 
or change in LV mass correspond to a reduction in LV 
mass of 12.3 g in the frequent-hemodialysis group, as 
compared with a reduction of 2.2 g in the conventional-
dialysis group (difference in medians, 10.1 g). The 
greater separation in the two curves on the right side 
of the graph of the change in LV mass is because nine 
patients had reductions in LV mass of at least 60 g; all 
of them were in the frequent-hemodialysis group. The 
median results for the composite outcome of death or 
change in physical-health composite score correspond 
to an increase in the physical-health composite score 
of 2 points in the frequent-hemodialysis group as com-
pared with no change in the conventional-dialysis group 
(difference in medians, 2 points). Changes in LV mass 
ranged from a decrease of 51.2 g to an increase of 68.8 g 
in the conventional-dialysis group and from a decrease 
of 174.5 g to an increase of 61.9 g in the frequent-hemo-
dialysis group. Changes in the physical-health compos-
ite score ranged from a decrease of 27 points to an in-
crease of 22 points in conventional-dialysis group, and 
from a decrease of 28 points to an increase of 29 points 
in the frequent-hemodialysis group. The standardized 
effect sizes for the main secondary outcomes (Panel C) 
were calculated as follows: the mean differences in LV 
mass, physical-health composite score (in which higher 
scores indicate better physical health), Beck Depression 
Inventory score (in which higher scores indicate more 
severe depression), albumin concentration before dialy-
sis, phosphorus concentration before dialysis, and sys-
tolic blood pressure before dialysis were divided by the 
baseline standard deviation; the mean difference in log 
dose of erythropoiesis-stimulating agent (ESA) was di-
vided by the standard deviation of the log baseline ESA 
dose; the log risk ratio for failure to complete the Trail 
Making Test Part B was divided by square root ([1 – p]/p), 
where p is the fraction of participants who did not com-
plete the test within 5 minutes at baseline; the log haz-
ard ratio for hospitalization unrelated to vascular access 
or death was divided by square root (1/p), where p is 
the fraction of patients with a hospitalization unrelated 
to vascular  access or death. ESA doses of less than 
5000 erythropoietin equivalent units were set to 5000 
before log transformation.
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and less variable time-averaged solute concentra-
tions), or improved control of extracellular vol-
ume excess (reducing the time-averaged fluid 
load). Consistently high weight gain between 
dialysis sessions may induce hypertension, left 
ventricular hypertrophy, and other adverse ef-
fects32-34; the lower weight gain between dialysis 
sessions in the frequent-hemodialysis group may 
be responsible for some of the benefit that we 
observed with respect to left ventricular mass. 
Although frequent hemodialysis is far from per-
fect, it may more closely approximate the capac-
ity of a native or transplanted kidney to regulate 
extracellular volume and solute composition.
However, the benefits of hemodialysis per-
formed six times per week were gained at the 
cost of more frequent interventions related to 
vascular access. Although we cannot exclude the 
possibility that these interventions were prompt-
ed by more frequent contact with the patient or 
by providers’ fears, the fact that needle cannula-
tion of a fistula or graft or manipulation of a 
catheter occurred approximately twice as fre-
quently in the frequent-hemodialysis group as in 
the conventional-dialysis group could have con-
tributed directly to the complications we observed.
The study has several strengths, including its 
relatively large sample size, the use of cardiac MRI 
for the assessment of left ventricular mass, the 
diversity of the study population, high adherence 
rates, and the wide array of outcomes linked to 
death and complications among patients with end-
stage renal disease.35,36 The study also has several 
important limitations. Owing to feasibility and 
other logistic concerns, the sample size was insuf-
ficient to determine the effects of frequent in-cen-
ter hemodialysis on death, cause-specific death, 
hospitalization, or other events. Although we de-
termined a priori that favorable effects on both 
coprimary composite outcomes would be required 
in order to consider the trial to have had positive 
results, the rate of death in both groups was low, 
Table 4. Adverse Events during the 12-Month Follow-up Period of the Study.*
Outcome
Conventional Hemodialysis
(N = 120)
Frequent Hemodialysis
(N = 125)
Hazard Ratio
(95% CI) P Value
no. of events
no. of patients 
with event no. of events
no. of patients 
with event
Death 9 5 — —
All hospitalizations 114 47 109 58 0.88 (0.60–1.28) 0.50
Unrelated to vascular access 90 44 79 47 0.80 (0.53–1.21) 0.30
Related to vascular access 24 14 30 20 0.99 (0.54–1.82) 0.97
Cardiovascular-related 15 12 17 15 0.83 (0.44–1.59) —
Infection related 27 20 27 23 0.83 (0.49–1.40) —
All interventions related to vascular access 65 29 95 47 1.35 (0.84–2.18) 0.22
Correction of access failure 23 15 19 15 0.71 (0.35–1.44) 0.35
Other procedures 42 21 76 38 1.71 (0.98–2.97) 0.06
Episodes of hypotension† 470 87 724 99 — —
Hypokalemia
Potassium <3.0 mmol/liter 0 0 0 0 — —
Potassium <3.5 mmol/liter 6 5 13 8 — 0.57‡
Hypophosphatemia§ 9 7 15 9 — 0.80‡
* The hazard ratios and P values for rates of events (including multiple events per patient) between the frequent-hemodialysis group and the 
conventional-hemodialysis group were calculated with the use of the Andersen–Gill model, except where otherwise noted.
† The percentage of dialysis treatments with recorded hypotensive episodes, defined as the need for a lower ultrafiltration rate, reduced blood 
flow, or saline administration to ameliorate hypotension, was 10.9% in the frequent-hemodialysis group and 13.6% in the conventional- 
hemodialysis group (P = 0.04 with the use of generalized estimating equations).
‡ The P values for the comparison of the number of patients with at least one event of hypokalemia or hypophosphatemia were calculated 
with the use of Fisher’s exact test.
§  Hypophosphatemia was defined as a phosphorus concentration of less than 2.17 mg per deciliter (0.7 mmol per liter).
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and the bulk of the treatment effect was seen in 
intermediate outcomes. Studies involving patients 
with37 and patients without38 end-stage renal dis-
ease have suggested that treatments targeted to 
reducing left ventricular mass are associated with 
lower rates of death and cardiovascular events. In 
observational analyses, differences in left ventricu-
lar mass33 and self-reported physical health39 of 
lesser magnitude than those shown in our study 
have been associated with significantly improved 
outcomes in this population. We excluded patients 
who had ample residual kidney function and pa-
tients who were not expected to survive for more 
than 6 months; we cannot generalize the study’s 
results to these large and important segments of 
the population undergoing hemodialysis. To limit 
the risk of the “false discovery” of multiple effects, 
we designated a single outcome for each domain 
as a key secondary outcome (except in the case of 
hypertension, for which we specified two main 
secondary outcomes). These designations were 
somewhat arbitrary.
In summary, as compared with conventional 
hemodialysis, frequent hemodialysis was associ-
ated with favorable changes in the composite 
coprimary outcomes of death or 12-month change 
in left ventricular mass and death or 12-month 
change in the RAND-36 physical-health compos-
ite score. Frequent hemodialysis improved the 
control of hypertension and hyperphosphatemia 
but had no significant effects on cognitive per-
formance, self-reported depression, serum albu-
min concentration, or use of erythropoiesis-stimu-
lating agents. Patients who underwent frequent 
hemodialysis were significantly more likely to 
undergo interventions related to vascular access. 
Before major changes in practice can be recom-
mended, the net effects of frequent hemodialysis 
will need to be balanced against the added bur-
den for the patient and societal cost.
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